No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
www.pharmaron.cnNo one on the platform currently holds 300759.SZ.
No tracked institution reports a position in 300759.SZ as of their last filing.
No one on the platform has traded 300759.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.1% | 10.4% | 10.8% | — | — | — |
| Rev. Growth % | 14.8% | 22.4% | ||||
| Profit Margin % | 11.8% | 15.2% | 14.6% | |||
| Free Cash Flow Margin % | 3.9% | -0.2% | -5.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $16.7B | +19.0% | $1.09 | $0.95–$1.16 | — | 7 |
| 2027 | $19.8B | +18.8% | $1.40 | $1.24–$1.46 | — | 8 |
| 2028 | $23.5B | +18.7% | $1.81 | $1.48–$2.45 | — | 9 |
| 2029 | $21.9B | -7.0% | $1.63 | $1.54–$1.70 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-20 | $0.24 | $0.23 | -4.2% |
| 2026-04-28 | $0.21 | $0.18 | -11.9% |
| 2026-03-30 | $0.28 | $0.30 | +7.1% |
| 2025-10-28 | $0.25 | $0.25 | -0.5% |
| 2025-08-21 | $0.24 | $0.22 | -10.2% |
| 2025-04-27 | $0.20 | $0.17 | -15.0% |
| 2025-03-25 | $0.27 | $0.21 | -22.2% |
| 2024-10-29 | $0.24 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300759.SZPharmaron Beijing Co., Ltd. | $42.41 | +0.12% | $62.7B | — |
| 002252.SZShanghai RAAS Blood Products Co., Ltd. | $4.88 | -0.61% | $32.2B | — |
| 002821.SZAsymchem Laboratories (Tianjin) Co., Ltd. | $177.55 | +0.20% | $59.1B | — |
| 300122.SZChongqing Zhifei Biological Products Co., Ltd. | $12.26 | +0.41% | $29.3B | — |
| 300832.SZShenzhen New Industries Biomedical Engineering Co., Ltd. |
| $0.17 |
| -29.2% |
| $48.84 |
| -0.22% |
| $38.4B |
| — |
| 300896.SZImeik Technology Development Co.,Ltd. | $87.74 | -0.68% | $26.5B | — |
| 600085.SSBeijing Tongrentang Co., Ltd | $23.25 | -0.30% | $31.9B | — |
Source: Financial Modeling Prep · peers by sector/industry